|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 833.6 DKK | -0.86% |
|
+3.37% | +8.06% |
| 06/06 | Transcript : Coloplast A/S - Analyst/Investor Day | |
| 15/05 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 |  |
Coloplast A/S updated earnings guidance for the year 2021/22. For the year, the organic revenue growth guidance is unchanged, expected around 7% at constant exchange rates. Reported growth in DKK excluding Atos Medical is expected to be around 9% from previously around 8% due to FX movements.
The impact of the Atos Medical acquisition on reported growth is expected to be around 6%-points (8 months impact). In total, reported growth is expected to be 15%.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.06% | 2.74TCr | |
| -41.00% | 262.71Cr | |
| +26.30% | 247.96Cr | |
| -23.19% | 230.54Cr | |
| +5.99% | 221.37Cr | |
| -14.16% | 181.09Cr | |
| +33.51% | 134.27Cr | |
| +27.17% | 132.22Cr | |
| +1.64% | 124.75Cr | |
| +31.91% | 103.62Cr |
COLOPLAST A/S 
